13G Filing: Sabby Capital and Anthera Pharmaceuticals Inc (ANTH)

Page 4 of 9 – SEC Filing

OO
CUSIP No.
03674U3001.
NAME OF REPORTING PERSONSHal Mintz2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) [_]

(b) [X]

3.
SEC USE ONLY4.
CITIZENSHIP OR PLACE OF ORGANIZATIONUSANUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.
SOLE VOTING POWER06.
SHARED VOTING POWER 691,0997.
SOLE DISPOSITIVE POWER08.
SHARED DISPOSITIVE POWER 691,0999.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 691,09910.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)

[_]11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)4.9912.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN?

CUSIP No.
03674U300

Item 1.
(a).
Name of Issuer:Anthera Pharmaceuticals, Inc.

(b).
Address of issuer’s principal executive offices:25801 Industrial Boulevard, Suite B
Hayward, California 94545

Item 2.
(a).
Name of person filing:Sabby Healthcare Master Fund, Ltd.
Sabby Volatility Warrant Master Fund, Ltd.
Sabby Management, LLC
Hal Mintz